Guideline Review: EASL Clinical Practice Guidelines: Drug-Induced Liver Injury (DILI)

Paul N. Brennan; Peter Cartlidge; Thomas Manship; John F. Dillon

doi:10.1136/flgastro-2021-101886

Guideline Review: EASL Clinical Practice Guidelines: Drug-Induced Liver Injury (DILI)

Paul N. Brennan (Lead / Corresponding author), Peter Cartlidge, Thomas Manship, John F. Dillon

Research output: Contribution to journal › Review article › peer-review

23 Citations (Scopus)

88 Downloads (Pure)

Abstract

The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.

Original language	English
Pages (from-to)	332-336
Number of pages	5
Journal	Frontline Gastroenterology
Volume	13
Issue number	4
Early online date	29 Jul 2021
DOIs	https://doi.org/10.1136/flgastro-2021-101886
Publication status	Published - Jul 2022

Keywords

drug induced hepatotoxicity
drug induced liver injury
drug metabolism
drug toxicity

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1136/flgastro-2021-101886Licence: CC BY-NC

Final Published VersionFinal published version, 303 KBLicence: CC BY-NC

Cite this

@article{89570587ddd34b54825cbf8e3a5d898e,

title = "Guideline Review: EASL Clinical Practice Guidelines: Drug-Induced Liver Injury (DILI)",

abstract = "The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.",

keywords = "drug induced hepatotoxicity, drug induced liver injury, drug metabolism, drug toxicity",

author = "Brennan, {Paul N.} and Peter Cartlidge and Thomas Manship and Dillon, {John F.}",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2022",

month = jul,

doi = "10.1136/flgastro-2021-101886",

language = "English",

volume = "13",

pages = "332--336",

journal = "Frontline Gastroenterology",

issn = "2041-4137",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - Guideline Review

T2 - EASL Clinical Practice Guidelines: Drug-Induced Liver Injury (DILI)

AU - Brennan, Paul N.

AU - Cartlidge, Peter

AU - Manship, Thomas

AU - Dillon, John F.

N1 - Publisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2022/7

Y1 - 2022/7

N2 - The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.

AB - The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.

KW - drug induced hepatotoxicity

KW - drug induced liver injury

KW - drug metabolism

KW - drug toxicity

U2 - 10.1136/flgastro-2021-101886

DO - 10.1136/flgastro-2021-101886

M3 - Review article

C2 - 35722609

SN - 2041-4137

VL - 13

SP - 332

EP - 336

JO - Frontline Gastroenterology

JF - Frontline Gastroenterology

IS - 4

ER -

Guideline Review: EASL Clinical Practice Guidelines: Drug-Induced Liver Injury (DILI)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this